Management of recurrent hepatitis C in liver transplant recipients

Infectious Disease Clinics of North America

Volumn 20, Issue 1, 2006, Pages 155-174

  Biggins, Scott W ^a   Terrault, Norah A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; HEPATITIS B ANTIBODY; HEPATITIS C ANTIBODY; IMMUNOSUPPRESSIVE AGENT; INTERFERON; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NUCLEOSIDE ANALOG; OKT 3; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PREDNISONE; RIBAVIRIN; STEROID; THYMOCYTE ANTIBODY; TSUKUBAENOLIDE;

ANEMIA; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CYTOPENIA; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; GRAFT FAILURE; GRAFT INFECTION; GRAFT RECIPIENT; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFECTION RISK; KIDNEY DISEASE; LEUKOPENIA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER GRAFT; LIVER TRANSPLANTATION; MAINTENANCE THERAPY; NONHUMAN; POSTOPERATIVE INFECTION; POSTOPERATIVE PERIOD; PREOPERATIVE TREATMENT; RECURRENT INFECTION; RETRANSPLANTATION; REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VIRUS LOAD;

EID: 33644760272     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2006.01.011     Document Type: Review

References (83)

1. United Network for Organ Sharing. Available at: www.unos.org. Accessed January 11, 2005.
2. G. Armstrong, M. Alter, and G. McQuillan The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States Hepatology 31 2000 777 782
3. H.B. El-Serag Hepatocellular carcinoma and hepatitis C in the United States Hepatology 36 2002 S74 S83
4. L.M. Forman, J.D. Lewis, and J.A. Berlin The association between hepatitis C infection and survival after orthotopic liver transplantation Gastroenterology 122 2002 889 896
5. M. Berenguer, L. Ferrell, and J. Watson HCV-related flbrosis progression following liver transplantation: increase in recent years J Hepatol 32 2000 673 684
6. A. Sanchez-Fueyo, J.C. Restrepo, and L. Quinto Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft Transplantation 73 2002 56 63
7. E. Gane, B. Portmann, and N. Naoumov Long-term outcome of hepatitis C infection after liver transplantation N Engl J Med 334 1996 815 820
8. S. Biggins, and N. Terrault Should HCV-related cirrhosis be a contraindication for retransplantation? Liver Transpl 9 2003 236 238
9. G. Everson Treatment of patients with hepatitis C virus on the waiting list Liver Transpl 9 2003 S90 S94
10. M. Garcia-Retortillo, X. Forns, and A. Feliu Hepatitis C virus kinetics during and immediately after liver transplantation Hepatology 35 2002 680 687
11. T. Fukumoto, T. Berg, and Y. Ku Viral dynamics of hepatitis C early after orthotopic liver transplantation: evidence for rapid turnover of serum virions Hepatology 24 1996 1351 1354
12. O. Chazouilleres, M. Kim, and C. Combs Quantitation of hepatitis C vims RNA in liver transplant recipients Gastroenterology 106 1994 994 999
13. R. Sreekumar, A. Gonzalez-Koch, and Y. Maor-Kendler Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation Hepatology 32 2000 1125 1130
14. M. Charlton, E. Seaberg, and R. Wiesner Predictors of patient and graft survival following liver transplantation for hepatitis C Hepatology 28 1998 823 830
15. S. Zhou, N. Terrault, and L. Ferrell Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: relationship to genotype and level of viremia Hepatology 24 1996 1041 1046
16. J. Crespo, B. Carte, and J.L. Lozano Hepatitis C virus recurrence after liver transplantation: relationship to anti-HCV core IgM, genotype, and level of viremia Am J Gastroentero 92 1997 1458 1462
17. E. Gane, N. Naoumov, and K. Qian A longitudinal analysis of hepatitis C virus replication following liver transplantation Gastroenferology 110 1996 167 177
18. S. Taga, M. Washington, and N. Terrault Cholestatic hepatitis C in liver allografts Liver Transpl Surg 4 1998 304 310
19. A. Doughty, J. Spencer, and Y. Cossart Cholestatic hepatitis after liver transplantation is associated with persistently high serum hepatitis C virus RNA levels Liver Transplant Surg 4 1998 15 21
20. R. Firpi, M. Abdelmalek, and C. Soldevila-Pico Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C Liver Transpl 8 2002 1000 1006
21. D. Gopal, and H. Rosen Duration of antiviral therapy for cholestatic HCV recurrence may need to be indefinite Liver Transpl 9 2003 348 353
22. C. Feray, L. Caccamo, and G.J. Alexander European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group Gastroenterology 17 1999 619 625
23. U. Neumann, T. Berg, and M. Bahra Fibrosis progression after liver transplantation in patients with recurrent hepatitis C J Hepatol 41 2004 830 836
24. M. Prieto, M. Berenguer, and J. Rayon High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes Hepatoiogy 29 1999 250 256
25. M. Berenguer, M. Prieto, and J.M. Rayon Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation Hepatology 32 2000 852 858
26. M. Guido, S. Fagiuoli, and G. Tessari Histology predicts cirrhotic evolution of post transplant hepatitis C Gut 50 2002 697 700
27. P. Thuluvath, and H. Yoo Graft and patient survival after adult live donor liver transplantation compared to a matched cohort who received a deceased donor transplantation Liver Transpl 10 2004 1263 1268
28. M. Russo, J. Galanko, and K. Beavers Patient and graft survival in hepatitis C recipients after adult living donor liver transplantation in the United States Liver Transpl 10 2004 340 346
29. A. Bozorgzadeh, A. Jain, and C. Ryan Impact of hepatitis C viral infection in primary cadaveric liver allograft versus primary living-donor allograft in 100 consecutive liver transplant recipients receiving tacrolimus Transplantation 77 2004 1066 1070
30. P. Gaglio, S. Malireddy, and B. Levitt Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors Liver Transpl 9 2003 1028 1035
31. M. Shiftman, R. Stravitz, and M. Contos Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation Liver Transpl 10 2004 1248 1255
32. M. Garcia-Retortillo, X. Forns, and J. Llovet Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation Hepatology 40 2004 699 707
33. U. Neumann, T. Berg, and M. Bahra Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up Transplantation 77 2004 226 231
34. J. Eason, G. Loss, and J. Blazek Steroid-free liver transplantation using rabbit antithymocyte globulin induction: results of a prospective randomized trial Liver Transpl 7 2001 693 697
35. G.V. Papatheodoridis, S. Davies, and A.P. Dhillon The role of different immunosuppression in the long-term histological outcome of HCV reinfection after liver transplantation for HCV cirrhosis Transplantation 72 2001 412 418
36. R.M. Ghobrial, D.G. Farmer, and A. Baquerizo Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience Ann Surg 229 1999 824 831
37. A.R. Mueller, K. Platz, and C. Wiilimski Influence of immunosuppression on patient survival after liver transplantation for hepatitis C Transplant Proc 33 2001 1347 1349
38. A. Jain, R. Kashyap, and A.J. Demetns A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C Liver Transpl 8 2002 40 46
39. A. Zekry, M. Gleeson, and S. Guney A prospective cross-over study comparing the effect of mycophenolate versus azathioprine on allograft function and viral load in liver transplant recipients with recurrent chronic HCV infection Liver Transpl 10 2004 52 57
40. M. Bahra, U. Neumann, and D. Jacob MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: impact on histological course Am J Transplant 5 2005 406 411
41. P. Neuhaus, P. Clavien, and D. Kittur Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial Liver Transpl 8 2002 132 142
42. Y. Calmus, J. Scheele, and I. Gonzalez-Pinto Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients Liver Transpl 8 2002 123 131
43. K.W. Burak, W.K. Kremers, and K.P. Batts Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after fiver transplantation for hepatitis C Liver Transpl 8 2002 362 369
44. G. McCaughan, and A. Zekry Impact of immunosuppression on immunopathogenesis of liver damage in hepatitis C virus-infected recipients following liver transplantation Liver Transpl 9 2003 S21 S27
45. D.R. Nelson, C. Soldevila-Pico, and A. Reed Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation Liver Transpl 7 2001 1064 1070
46. M. Berenguer, M. Prieto, and F. San Juan Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients Hepatology 36 2002 202 210
47. M. Wali, R.F. Harrison, and P.J. Gow Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C Gut 51 2002 248 252
48. M. Charlton, and E. Seaberg Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database Liver Transpl Surg 5 1999 S107 S114
49. A. Regev, E. Molina, and R. Maura Reliability of histopathologic assessment for the differentiation of recurrent hepatitis C from acute rejection after liver transplantation Liver Transpl 10 2004 1233 1239
50. R. McTaggart, N. Terrault, and A. Vardanian Hepatitis C etiology of liver disease is strongly associated with early acute rejection following liver transplantation Liver Transpl 10 2004 975 985
51. R. Wiesner, M. Sorrell, and F. Villamil International Liver Transplantation Society Expert Panel. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C Liver Transpl 9 2003 S1 S9
52. A. Shergill, M. Khalili, and K. Bellinger Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C infected patients undergoing liver transplantation Am J Transplant 5 2005 118 124
53. R. Stravitz, M. Shiftman, and A. Sanyal Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation Liver Transpl 10 2004 850 858
54. S. Saab, D. Kalmaz, and N. Gajjar Outcomes of acute rejection after interferon therapy in liver transplant recipients Liver Transpl 10 2004 859 867
55. D. Samuel, T. Bizollon, and C. Feray Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study Gastroenterology 124 2003 642 650
56. T. Bizollon, S. Ahmed, and S. Radenne Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence Gut 52 2003 283 287
57. E. Giostra, G. Kullak-Ublick, and W. Keller Ribavirin/interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantation Transpl Int 17 2004 169 176
58. M. Abdelmalek, R. Firpi, and C. Soldevila-Pico Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C Liver Transpl 10 2004 199 207
59. S. Mukherjee, J. Rogge, and L. Weaver Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation Transplant Proc 35 2003 3042 3044
60. J. Dumortier, J. Scoazec, and P. Chevallier Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination J Hepatol 40 2004 669 674
61. A.O. Shakil, B. McGuire, and J. Crippin A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C Hepatology 36 2002 1253 1258
62. B. Lavezzo, A. Franchello, and A. Smedile Treatment of recurrent hepatitis C in liver transplants: efficacy of a six versus a twelve month course of interferon alfa 2b with ribavirin J Hepatol 37 2002 247 252
63. K.V. Narayanan Menon, J.J. Poterucha, and O.M. El-Amin Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy Liver Transpl 8 2002 623 629
64. C. Feray, D. Samuel, and M. Gigou An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection Hepatology 22 1995 1084 1089
65. N. Terrault Hepatitis B and liver transplantation Semin Gastrointest Dis 11 2000 96 114
66. Feray C, Gigou M, Samuel D, et al. Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation. Ann Intern Med I998;128:810-6.
67. K. Krawczynski, M. Alter, and D. Tankersley Effect of immune globulin on the prevention of experimental hepatitis C virus infection J Infect Dis 173 1996 822 828
68. N. Terrault Prophylactic and preemptive therapies for hepatitis C virus-infected patients undergoing liver transplantation Liver Transpl 9 2003 S95 S100
69. B. Willems, P. Marotta, and P.D. Greig Anti-HCV immunoglobulins for the prevention of graft infection in HCV-related liver transplantation J Hepatol 36 2002 S96A
70. G.L. Davis, D.R. Nelson, and N.A. Terrault A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients Liver Transpl 11 2005 941 949
71. P. Sheiner, P. Boros, and F. Klion The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation Hepatology 28 1998 831 838
72. K. Reddy, D. Wippler, and X. Zervos Recurrent HCV infection following liver transplantation: the role of early post transplant interferon treatment Hepatology 24 1996 295A
73. N. Singh, T. Gayowski, and C.F. Wannstedt Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: a prospective, randomized, controlled trial Transplantation 65 1998 82 86
74. N. Chalasani, C. Manzarbeitia, and P. Ferenci Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials Hepatology 41 2005 Feb 289 298
75. V. Mazzaferro, A. Tagger, and M. Schiavo Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment Transplant Proc 33 2001 1355 1357
76. Y. Sugawara, M. Makuuchi, and Y. Matsui Preemptive therapy for hepatitis C virus after living-donor liver transplantation Transplantation 78 2004 1308 1311
77. S. Saab, D. Ly, and S.B. Han Is it cost-effective to treat recurrent hepatitis C injection in OLT patients Liver Transpl 8 2002 449 457
78. W. Wall, and A. Khakhar Retransplantation for recurrent hepatitis C: the argument against Liver Transpl 9 2003 S73 S78
79. H.R. Rosen, J.P. Madden, and P. Martin A model to predict survival following liver retransplantation Hepatology 29 1999 365 370
80. G. Neff, C. O'Brien, and J. Nery Factors that identify survival after liver retransplantation for allograft failure caused by recurrent hepatitis C infection Liver Transpl 10 2004 1497 1503
81. H. Rosen Validation and refinement of survival models for liver retransplantation Hepatology 38 2003 460 469
82. J.J. Burton, A. Sonnenberg, and H. Rosen Retransplantation for recurrent hepatitis C in the MELD era: maximizing utility Liver Transpl 10 Suppl 2 2004 S59 S64
83. L. Castells, V. Vargas, and H. Allende Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation J Hepatol 43 2005 53 59